WWWenhui Wang

Wenhui Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wenhui Wang has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Xiaorong Hou

    Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    4 shared publications
  • Ke Hu

    Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

    3 shared publications
  • Fuquan Zhang

    Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    2 shared publications
  • Fuquan Zhang

    Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    2 shared publications
  • Kang Ren

    Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    2 shared publications
  • Shuai Sun

    Department of Radiation Oncology Peking Union Medical College Hospital Chinese Academy of Medical Science & Peking Union Medical College Beijing China

    2 shared publications

Latest Publications

  • Open Access

    Annual hazard rates for early-stage endometrial carcinoma after postoperative radiotherapy under FIGO 2023 staging system: results from a population-based single-center cohort study

    by Lingxia Xin, Kang Ren, Zihan Yan, Jiabin Ma, Wenhui Wang, Yunlong Sheng, Yaqi Wang, Xiaorong Hou, Fuquan Zhang

    Xin L, et al. J Gynecol Oncol. 2026 ;37:e107. https://doi.org/10.3802/jgo.2026.37.e107

  • Open Access

    Timing of adjuvant radiotherapy for early-stage endometrial carcinoma: a single-center retrospective cohort study

    by Zihan Yan, Wenhui Wang, Shuning Jiao, Kang Ren, Xiaorong Hou, Ke Hu, Fuquan Zhang

    Yan Z, et al. J Gynecol Oncol. 2025 Aug;37:e14. https://doi.org/10.3802/jgo.2026.37.e14

  • Open Access

    Recurrent patterns after postoperative radiotherapy for early stage endometrial cancer: A competing risk analysis model

    by Kang Ren, Wenhui Wang, Shuai Sun, Xiaorong Hou, Ke Hu, Fuquan Zhang

    Objective: The study aimed to evaluate site‐specific recurrent patterns via competing risks analysis and hazard function to provide evidence for adjuvant treatment and follow‐up for early staged endometrial cancer (EC).Methods: A total of 858 patients with International Federation of Gynecology and Obstetrics stage I–II EC who received adjuvant radiotherapy at our institution (2000–2017) were included. The radiotherapy modality comprised external beam radiotherapy (EBRT) with or without vaginal brachytherapy (VBT) or VBT alone. Competing risks analysis and hazard rate function were employed to evaluate the recurrence rate according to the ESMO–ESGO–ESTRO risk classification.Results: The 5‐year overall survival rates of the low‐risk (LR), intermediate‐risk (IR), high–intermediate risk (HIR), and high‐risk (HR) groups were 96.1%, 95%, 93%, and 89.7%, respectively (p = 0.018). Sixty‐eight patients developed recurrence. The 5‐year incidence of distant recurrence was the highest in the HR group (14.87%), followed by the HIR (7.71%), IR (5.27%), and LR (1.26%) groups (Gray's test, p < 0.001). The LR and IR groups showed late metastasis behaviors for distant metastasis. The HR group presented a large magnitude of distant metastasis with an early peak that increased beyond 3 years. Subgroup analysis revealed that EBRT±VBT tended to reduce the locoregional relapse rate compared with VBT in the HIR–HR group (2.36% vs. 7.73%, Gray's test, p = 0.08).Conclusion: The established competing risk modeling demonstrated different recurrence patterns across the risk groups and radiotherapy modes. A better understanding of the change in site‐specific recurrence behavior allows more targeted adjuvant treatment and surveillance regimens.


  • Open Access

    Treatment optimization of pelvic external beam radiation and/or vaginal brachytherapy for patients with stage I to II high-risk Endometrioid adenocarcinoma: a retrospective multi-institutional analysis

    by Wenhui Wang, Lijuan Zou, Tiejun Wang, Zi Liu, Jianli He, Xiaoge Sun, Wei Zhong, Fengju Zhao, Xiaomei Li, Sha Li, et al.

    For stage I to II high-risk endometrioid adenocarcinoma patients, the optimal adjuvant radiotherapy modality remains controversial. The present study sought to optimize the treatment of pelvic external beam radiation (EBRT) with/or vaginal brachytherapy (VBT) for high-risk endometrioid adenocarcinoma patients in multiple radiation oncology centers across China. This article retrospectively reviewed stage I to II patients with resected endometrioid adenocarcinoma treated at 13 radiation centers from 1999 to 2015. Patients were eligible if they had high-risk features (stage IB Grade 3 disease or stage II Grade 1–3 disease) on the basis of ESMO-ESGO-ESTRO risk group consensus. A total of 218 patients were included. Fifty-one patients received EBRT, 25 patients received VBT, and 142 patients were administered EBRT combined with VBT. The three groups were comparable in baseline characteristics, except the proportion of stage IB and Grade 3 disease in the VBT group was significantly higher and their age was older. Survival analysis showed that OS, DFS, LRFS and DMFS were significantly different among the three groups. Two out of three groups were compared with each other, and results demonstrated that DFS, LRFS and DMFS were worse in the VBT group than in the EBRT or EBRT + VBT group. The 3-year OS rates were 95.2, 85.2 and 95.1% in the EBRT, VBT and EBRT + VBT groups, respectively (p = 0.043). There was no significant difference in survival outcomes between EBRT group and EBRT + VBT group. A propensity matching analysis was performed to eliminate group differences. The results demonstrated that DFS and LRFS were significantly improved in the pelvic radiation group compared to the VBT group. Distant failure accounted for most of the failure patterns. Patients in the VBT group had significantly increased local and regional recurrence rates than patients in the EBRT or EBRT + VBT group. Acute and chronic radiation-induced toxicities were well tolerated for all patients. For patients with postoperative stage I to II high-risk endometrioid adenocarcinoma, compared with VBT alone, radiotherapy modalities including EBRT significantly improved DFS, LRFS and DMFS with tolerable adverse effects. Overall survival was not significantly different between EBRT and EBRT + VBT modalities.